Akebia Therapeutics (STU:AX9) Dividends Received


STU:AX9 Akebia Therapeutics Inc STU:AX9
45 GF Score
Price €1.19
GF Value €1.13
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Akebia Therapeutics Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:AX9
45GF Score
Akebia Therapeutics Inc STU:AX9
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Akebia Therapeutics (STU:AX9) Overvalued in 2026?

Based on GuruFocus' analysis, Akebia Therapeutics stock appears to be overvalued. The current stock price of €1.19 is trading 5.2% above its estimated GF Value™ of €1.13. GuruFocus considers Akebia Therapeutics to be Fairly Valued.

Key valuation signals for STU:AX9:

  • Dividends Received:
  • GF Value™: €1.13 vs. price of €1.19 (5.2% above fair value)
  • GF Score™: 45/100 with 5 warning signs

No single metric tells the full story. See the STU:AX9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Akebia Therapeutics Business Description

Other Exchanges AKBA:USA
Address 245 First Street, Suite 1400, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
45GF Score

Get the complete analysis for STU:AX9

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.19
Price
€1.13
GF Value